Matches in UGent Biblio for { <https://biblio.ugent.be/publication/2047330#aggregation> ?p ?o. }
Showing items 1 to 48 of
48
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B404219.
- aggregation creator B404220.
- aggregation creator B404221.
- aggregation creator B404222.
- aggregation creator B404223.
- aggregation creator B404224.
- aggregation creator B404225.
- aggregation creator B404226.
- aggregation creator B404227.
- aggregation creator B404228.
- aggregation creator B404229.
- aggregation creator B404230.
- aggregation creator B404231.
- aggregation creator B404232.
- aggregation creator B404233.
- aggregation creator B404234.
- aggregation creator person.
- aggregation date "2011".
- aggregation format "application/pdf".
- aggregation hasFormat 2047330.bibtex.
- aggregation hasFormat 2047330.csv.
- aggregation hasFormat 2047330.dc.
- aggregation hasFormat 2047330.didl.
- aggregation hasFormat 2047330.doc.
- aggregation hasFormat 2047330.json.
- aggregation hasFormat 2047330.mets.
- aggregation hasFormat 2047330.mods.
- aggregation hasFormat 2047330.rdf.
- aggregation hasFormat 2047330.ris.
- aggregation hasFormat 2047330.txt.
- aggregation hasFormat 2047330.xls.
- aggregation hasFormat 2047330.yaml.
- aggregation isPartOf urn:issn:0923-7534.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)".
- aggregation abstract "BACKGROUND: We recently published the results of the PCI99 randomised trial comparing the effect of a prophylactic cranial irradiation (PCI) at 25 or 36 Gy on the incidence of brain metastases (BM) in 720 patients with limited small-cell lung cancer (SCLC). As concerns about neurotoxicity were a major issue surrounding PCI, we report here midterm and long-term repeated evaluation of neurocognitive functions and quality of life (QoL). PATIENTS AND METHODS: At predetermined intervals, the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and brain module were used for self-reported patient data, whereas the EORTC-Radiation Therapy Oncology Group Late Effects Normal Tissue-Subjective, Objective, Management, Analytic scale was used for clinicians' assessment. For each scale, the unfavourable status was analysed with a logistic model including age, grade at baseline, time and PCI dose. RESULTS: Over the 3 years studied, there was no significant difference between the two groups in any of the 17 selected items assessing QoL and neurological and cognitive functions. We observed in both groups a mild deterioration across time of communication deficit, weakness of legs, intellectual deficit and memory (all P < 0.005). CONCLUSION: Patients should be informed of these potential adverse effects, as well as the benefit of PCI on survival and BM. PCI with a total dose of 25 Gy remains the standard of care in limited-stage SCLC.".
- aggregation authorList BK716763.
- aggregation endPage "1163".
- aggregation issue "5".
- aggregation startPage "1154".
- aggregation volume "22".
- aggregation aggregates 2047372.
- aggregation isDescribedBy 2047330.
- aggregation similarTo mdq576.
- aggregation similarTo LU-2047330.